TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:29
Coya Therapeutics Inc. ( COYA )
6.81USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
COYA
0.00%
SPY
30.72%
COYA
0.00%
SPY
112.82%
COYA
0.00%
SPY
201.04%
COYA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
67.75
82.79
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.09
0.00
6.71
0.00
0.00
-7.08
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-119.56
-323.35
0.00
Other Earnings and Cash Flow Stats:
Coya Therapeutics Inc. ( COYA ) Net Income TTM ($MM) is -14.23
Coya Therapeutics Inc. ( COYA ) Operating Income TTM ($MM) is -11.13
Coya Therapeutics Inc. ( COYA ) Owners' Earnings Annual ($MM) is 0.00
Coya Therapeutics Inc. ( COYA ) Current Price to Owners' Earnings ratio is 0.00
Coya Therapeutics Inc. ( COYA ) EBITDA TTM ($MM) is -11.10
Coya Therapeutics Inc. ( COYA ) EBITDA Margin is 0.00%
Capital Allocation:
Coya Therapeutics Inc. ( COYA ) has paid 0.00 dividends per share and bought back -0.268507 million shares in the past 12 months
Coya Therapeutics Inc. ( COYA ) has increased its debt by 2.24096 million USD in the last 12 months
Capital Structure:
Coya Therapeutics Inc. ( COYA ) Interest-bearing Debt ($MM) as of last quarter is 25
Coya Therapeutics Inc. ( COYA ) Annual Working Capital Investments ($MM) are -5
Coya Therapeutics Inc. ( COYA ) Book Value ($MM) as of last quarter is 10
Coya Therapeutics Inc. ( COYA ) Debt/Capital as of last quarter is -309%
Other Balance Sheet Stats:
Coya Therapeutics Inc. ( COYA ) has 10 million in cash on hand as of last quarter
Coya Therapeutics Inc. ( COYA ) has 1 million of liabilities due within 12 months, and long term debt 12 as of last quarter
Coya Therapeutics Inc. ( COYA ) has 9 common shares outstanding as of last quarter
Coya Therapeutics Inc. ( COYA ) has 8 million USD of preferred stock value
Academic Scores:
Coya Therapeutics Inc. ( COYA ) Altman Z-Score is 17.07 as of last quarter
Coya Therapeutics Inc. ( COYA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Coya Therapeutics Inc. ( COYA ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Coya Therapeutics Inc. ( COYA ) for the amount of $ on
10.02% of Coya Therapeutics Inc. ( COYA ) is held by insiders, and 14.13% is held by institutions
Coya Therapeutics Inc. ( COYA ) went public on 2022-12-29
Other Coya Therapeutics Inc. ( COYA ) financial metrics:
FCF:-9.89
Unlevered Free Cash Flow:0.00
EPS:-1.38
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-135.67
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Coya Therapeutics Inc. ( COYA ) :
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.